Sanofi: Leukemia, Lymphocytic, Chronic, B-Cell trials
The registry lists 11 Leukemia, Lymphocytic, Chronic, B-Cell studies with Sanofi as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 3Phase 2 3Phase 3 2Phase 4 1No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic LeukemiaCompletedNCT00328198Phase 2Results posted
- Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)CompletedNCT00206726Phase 2Results posted
- Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) PatientsCompletedNCT00086580Phase 3Results posted
- Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT01410513Phase 1
- A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT00923182Phase 1
- Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic LeukemiaTerminatedNCT00836043
- Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00694590Phase 1
- Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)CompletedNCT00464633Phase 2
- Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)CompletedNCT00344825
- A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or ThrombocytopeniaCompletedNCT00220311Phase 4
- Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic LeukemiaCompletedNCT00046683Phase 3